Lytgobi (futibatinib)

General Description

Lytgobi (futibatinib) is a kinase inhibitor approved for the treatment of adult patients with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma that harbors FGFR2 (fibroblast growth factor receptor 2) gene fusions or other rearrangements. The U.S. FDA granted its approval on September 22, 2022.

Getting Lytgobi (futibatinib) in India

Lytgobi (futibatinib)is approved in the U.S., Europe, and other countries, but it is not yet commercially available in India. However, eligible patients in India may access this important therapy through the Named Patient Program (NPP).

MitoGENE helps patients obtain Lytgobi (futibatinib) legally and safely, in collaboration with their treating doctor. We assist with documentation, import coordination, and delivery—ensuring full compliance with Indian regulatory guidelines.

If you or a loved one needs Lytgobi (futibatinib), MitoGENE is here to guide you through every step of the process.

Disease Indications:Bile Duct Cancer

Manufacturer:Taiho Pharmaceuticals

Usage:Oral

Medicine Approved by:

• European Medical Agency (EMA)
• Food and Drug Administration (FDA)
• Pharmaceuticals and Medical Devices Agency (PMDA)

Available Dosage Form & Package:

• 35 tablets x 4 mg (7-day supply for 20 mg/day

Shipping:

Room Temperature Shipping.  Lytgobi is shipped under controlled room temperature conditions (15°C to 25°C) using standard logistics procedures.